VACCINES News & Analysis

All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far. 

Fresh pandemic fears may stoke demand for these vaccine makers.

We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.

Are there still opportunities in the biotech sector now the covid-19 vaccine roll out is underway? We ask International Biotechnology Trust manager...

A resurgence in domestic travel is tipped to tide travel operators over until international borders open.

We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.

Subsectors such as biotechnology, pharmaceuticals and diagnostics feature some globally listed names that are trading at discounts.

Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.

Covid will create a $52bn vaccine and treatment market and usher in immunity by 2023, writes Morningstar's Karen Andersen.

The plasma giant remains overvalued, according to Morningstar.